Role of Transplant for Lymphoma

Daniel J. Landsburg, MD, reviews clinical trials from ASH 2016 pertinent to the role of auto stem cell transplantation (ASCT) following primary therapy for the lymphomas, including relapsed/refractory large B cell lymphoma, double-hit lymphoma, peripheral T-cell lymphoma, Hodgkin and non-Hodgkin’s Lymphoma and follicular lymphoma.

Depending upon disease state, considerations affecting outcome in these studies, according to Dr. Landsburg, included the presence of high risk features, early relapse, type and intensity of frontline therapy, timing of SCT, depth and timing of first remission and time to progression. Includes a discussion of a study ongoing at Penn Medicine that has found that lenalidomide maintenance after ASCT in patients with high-risk relapsed/refractory lymphoma compares favorably to historical controls who were PET positive prior to ASCT.